Search reports, ask a question, or jump to a page.
The problem
Intervention: Microarray patch (MAP) vaccination as an alternative needle-free delivery technology
Who it was tested with: 102 parents of children aged ≤18 years residing in Australia, Canada, the United Kingdom, or New Zealand (mean parental age 40.7 years).
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"A cross-sectional online survey was conducted to assess parents' perceptions of MAP safety, usability, and acceptability for themselves and their children." The study uses self-reported perceptions rather than observational or experimental measures of vaccination behavior or outcomes.
Small sample size (N=102) with predominance from Canada (59.8%) and Australia (35.3%); only measures perceived acceptability without data on actual uptake, clinical efficacy, or long-term outcomes; preliminary cross-sectional design without comparison group
Across countries and designs
1 study · 4 countries
